External validation of disease-free survival at 2 or 3 years as a surrogate and new primary endpoint for patients undergoing radical cystectomy for urothelial carcinoma of the bladder

European Journal of Surgical Oncology

Volumn 38, Issue 7, 2012, Pages 637-642

  Nuhn, P ^a   May, M ^b   Fritsche, H M ^c   Buchner, A ^a   Brookman May, S ^c   Bolenz, C ^d   Moritz, R ^e   Herrmann, E ^e   Burger, M ^c   Hofner T ^d   Ellinger, J ^f   Tilki, D ^a   Roigas, J ^g   Zacharias, M ^h   Trojan, L ^d   Wulfing C ^e   May, F ^a   Melchior, S ⁱ   Haferkamp, A ^j   Gilfrich, C ^b   Hohenfellner, M ^d   Wieland, W F ^c   Muller S C ^f   Stief, C G ^a   Bastian, P J ^a   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Urologische Klinik   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f UNIVERSITY OF BONN   (Germany)

^g VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^h Vivantes Klinikum AVK Berlin   (Germany)

ⁱ KLINIKUM BREMEN MITTE   (Germany)

^j GOETHE UNIVERSITY   (Germany)

more..

Author keywords

Bladder cancer; Disease free survival; Primary endpoint; Prognosis; Radical cystectomy; Urothelial carcinoma

Indexed keywords

BLADDER CARCINOMA; CANCER INVASION; CANCER SURGERY; CYSTECTOMY; DISEASE FREE SURVIVAL; EXTERNAL VALIDITY; HUMAN; KAPPA STATISTICS; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA;

EID: 84862199396     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2012.02.187     Document Type: Article

References (19)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics CA Cancer J Clin 60 5 2010 277 300 [Epub 2010/07/09]
2. A. Stenzl, N.C. Cowan, M. De Santis, M.A. Kuczyk, A.S. Merseburger, and M.J. Ribal Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 6 2011 Jun 1009 1018
3. A.H. Feifer, J.M. Taylor, T.V. Tarin, and H.W. Herr Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy Eur Urol 59 6 2011 Jun 978 984
4. M. May, E. Herrmann, C. Bolenz, A. Tiemann, S. Brookman-May, and H.M. Fritsche Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy Eur Urol 59 5 2011 May 712 718
5. M. May, E. Herrmann, C. Bolenz, S. Brookman-May, A. Tiemann, and R. Moritz Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy Ann Surg Oncol 18 7 2011 Jul 2018 2025
6. G. Sonpavde, M.M. Khan, and S.P. Lerner Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer J Urol 185 2 2011 456 461 [Epub 2010/12/21]
7. F. Calabro, and C.N. Sternberg Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer Eur Urol 55 2 2009 348 358 [Epub 2008/11/04]
8. G. Novara, K. Matsumoto, and W. Kassouf Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study Eur Urol 57 6 2010 1064 1071 [Epub 2010/01/15]
9. G. Novara, R.S. Svatek, and P.I. Karakiewicz Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4400 patients J Urol 183 6) 2010 2165 2170 [Epub 2010/04/20]
10. M. May, S. Brookman-Amissah, and J. Roigas Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications Eur Urol 57 5 2009 850 858 [Epub 2009/04/07]
11. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1 1977 159 174 [Epub 1977/03/01] (Pubitemid 8054849)
12. T.R. Fleming, and D.L. DeMets Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 7 1996 605 613 [Epub 1996/10/01] (Pubitemid 126450094)
13. J.J. Driscoll, and O. Rixe Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials Cancer J 15 5 2009 401 405 [Epub 2009/10/15]
14. S.F. Shariat, P.I. Karakiewicz, and G.S. Palapattu Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium J Urol 176 6 Pt 1 2006 2414 2422 discussion 22. [Epub 2006/11/07] (Pubitemid 44755069)
15. D.J. Sargent, S. Patiyil, and G. Yothers End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group J Clin Oncol 25 29 2007 4569 4574 [Epub 2007/09/19] (Pubitemid 350035314)
16. D.J. Sargent, H.S. Wieand, and D.G. Haller Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials J Clin Oncol 23 34 2005 8664 8670 [Epub 2005/11/02] (Pubitemid 46211509)
17. A. Choudhury, L.D. Nelson, and M.T. Teo MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer Cancer Res 70 18 2010 7017 7026 [Epub 2010/09/17]
18. E. Dudziec, J.R. Goepel, and J.W. Catto Global epigenetic profiling in bladder cancer Epigenomics 3 1 2011 35 45 [Epub 2011/12/01]
19. S.F. Shariat, R.F. Youssef, and A. Gupta Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers J Urol 183 5 2010 1744 1750 [Epub 2010/03/20]